RxDoctor Payments Data

Mary Mackenzie, MD

Family Medicine · Cary, NCNPI 1508801283

Payments from drug & device makers

$5,211in general payments, 2019–2025

Across 112 payments — averaging $46.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • Amgen$604
  • AstraZeneca$479
  • Lilly USA, LLC$372
  • AbbVie$304
  • Biohaven Pharmaceutical Holding Company Ltd.$258
  • plus $623 from 7 others

What the payments were for

  • Food & beverage$5,209100%
  • Education$20%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,211 in reported general payments places this provider in the 90th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$50,166
Medicare patients
88
Services billed
896

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide35$57,376
OzempicSemaglutide33$47,019
EliquisApixaban19$20,319
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$16,911
FarxigaDapagliflozin Propanediol15$14,763
Telmisartan53$2,115
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen51$1,857
Levothyroxine Sodium121$1,734
Bupropion XlBupropion Hcl53$1,506
Duloxetine Hcl19$1,453
Gabapentin86$1,432
Rosuvastatin Calcium107$1,393
Famotidine67$1,330
Estradiol22$1,189
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen45$1,089

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$372$57,37635 claims
Novo NordiskOzempic$2,572$47,01933 claims
PfizerEliquis$92$20,31919 claims
AstraZenecaFarxiga$479$14,76315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Cary

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →